Related Experiment Videos

[Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003]

Tomomi Abe1, Tetsufumi Koga, Yuki Sato

  • 1Biological Research Laboratories, Sankyo Co., Ltd.

Insights

Panipenem/betamipron (PAPM) maintains potent activity against clinical bacterial isolates in Japan. However, resistance rates for penicillin-resistant Streptococcus pneumoniae (PRSP) and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR) are increasing.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Context:

  • Post-marketing surveillance of panipenem/betamipron (PAPM) in Japan.
  • Annual monitoring of Minimum Inhibitory Concentrations (MICs) and resistance rates for beta-lactam antibacterials.
  • Data collected from 15 medical institutions over three years (2000-2003).

Purpose:

  • To evaluate the ongoing activity and resistance trends of PAPM against various clinical bacterial isolates.
  • To assess changes in resistance rates for key pathogens including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa.
  • To inform clinical practice regarding the efficacy of PAPM and the emergence of resistant strains.

Summary:

  • PAPM demonstrated consistent potent activity across three years of surveillance, comparable to pre-launch levels.
  • Significant increases in resistance were observed for penicillin-resistant Streptococcus pneumoniae (PRSP) and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (BLNAR).
  • Metallo-beta-lactamase-producing Pseudomonas aeruginosa also showed high resistance, while extended-spectrum beta-lactamase (ESBL)-producing strains showed variable rates.

Impact:

  • PAPM remains an effective therapeutic option, particularly against PRSP.
  • The rising incidence of PRSP and BLNAR necessitates careful monitoring and strategic antibiotic use.
  • Findings highlight the need for continued surveillance to track evolving antimicrobial resistance patterns.